These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36129396)

  • 21. Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy.
    Wei W; Knapp K; Wang L; Chen CI; Craig GL; Ferguson K; Schwartzman S
    Adv Ther; 2017 Aug; 34(8):1936-1952. PubMed ID: 28674959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obesity and Response to Advanced Therapies in Rheumatoid Arthritis.
    Baker JF; Reed G; Poudel DR; Harrold LR; Kremer JM
    Arthritis Care Res (Hoboken); 2022 Nov; 74(11):1909-1916. PubMed ID: 35143117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Ren S; Simpson E; Clowes M; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Dec; 36(12):1427-1437. PubMed ID: 29882210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease.
    Jin Y; Kang EH; Brill G; Desai RJ; Kim SC
    J Rheumatol; 2018 Aug; 45(9):1240-1248. PubMed ID: 29764964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
    Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
    Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
    Kavanaugh A; Lee SJ; Curtis JR; Greenberg JD; Kremer JM; Soto L; Etzel CJ; Cox V; Yoshida K; Reed GW; Solomon DH
    Ann Rheum Dis; 2015 Jun; 74(6):1150-5. PubMed ID: 25471471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register.
    Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Kalstad S; Kaufmann C; Rødevand E; Kvien TK
    Ann Rheum Dis; 2011 Dec; 70(12):2103-10. PubMed ID: 21875874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physician- and Patient-reported Effectiveness Are Similar for Tofacitinib and TNFi in Rheumatoid Arthritis: Data From a Rheumatoid Arthritis Registry.
    Movahedi M; Cesta A; Li X; Keystone EC; Bombardier C;
    J Rheumatol; 2022 May; 49(5):447-453. PubMed ID: 35169051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Machine Learning Approach for Prediction of CDAI Remission with TNF Inhibitors: A Concept of Precision Medicine from the FIRST Registry.
    Sonomoto K; Fujino Y; Tanaka H; Nagayasu A; Nakayamada S; Tanaka Y
    Rheumatol Ther; 2024 Jun; 11(3):709-736. PubMed ID: 38637465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methotrexate, Tofacitinib, and Biologic Disease-Modifying Antirheumatic Drug Safety and Effectiveness Among Patients with Rheumatoid Arthritis in Japan: CorEvitas Registry Observational Study.
    Tanaka Y; Kishimoto M; Sonomoto K; Amano K; Harigai M; Onofrei A; O'Brien J; Margolin Z; Barr C; Mizuno Y; Agarwal E; Sugiyama N; Yamanaka H
    Rheumatol Ther; 2024 Oct; 11(5):1237-1253. PubMed ID: 39066962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.
    Charles-Schoeman C; Buch MH; Dougados M; Bhatt DL; Giles JT; Ytterberg SR; Koch GG; Vranic I; Wu J; Wang C; Kwok K; Menon S; Rivas JL; Yndestad A; Connell CA; Szekanecz Z
    Ann Rheum Dis; 2023 Jan; 82(1):119-129. PubMed ID: 36137735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
    Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis.
    Kavanaugh A; van Vollenhoven RF; Fleischmann R; Emery P; Sainsbury I; Florentinus S; Chen S; Guérette B; Kupper H; Smolen JS
    Ann Rheum Dis; 2018 Feb; 77(2):289-292. PubMed ID: 29146743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.
    Lauper K; Mongin D; Iannone F; Kristianslund EK; Kvien TK; Nordström DC; Pavelka K; Pombo-Suarez M; Rotar Z; Santos MJ; Codreanu C; Lukina G; Gale SL; John M; Luder Y; Courvoisier DS; Gabay C
    Semin Arthritis Rheum; 2020 Feb; 50(1):17-24. PubMed ID: 31280937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does the Type of Failure and the Choice of the Second Biologic Influence Response and Persistence on Medication in Rheumatoid Arthritis?
    Bessette L; Movahedi M; Reed G; Kremer JM; Kane K; Keystone E
    J Clin Rheumatol; 2023 Oct; 29(7):332-340. PubMed ID: 37644656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data.
    Pappas DA; Litman HJ; Lesperance T; Kricorian G; Karis E; Rebello S; Hua W; Accortt NA; Stryker S
    Rheumatol Int; 2021 Feb; 41(2):381-390. PubMed ID: 32876744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis.
    Ho Lee Y; Gyu Song G
    Z Rheumatol; 2023 Apr; 82(3):248-255. PubMed ID: 34223982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.
    Harrold LR; Litman HJ; Saunders KC; Dandreo KJ; Gershenson B; Greenberg JD; Low R; Stark J; Suruki R; Jaganathan S; Kremer JM; Yassine M
    Arthritis Res Ther; 2018 Jan; 20(1):2. PubMed ID: 29329557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
    Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Lexberg AS; Rødevand E; Kalstad S; Mikkelsen K; Kvien TK
    Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
    Harrold LR; Reed GW; Solomon DH; Curtis JR; Liu M; Greenberg JD; Kremer JM
    Arthritis Res Ther; 2016 Dec; 18(1):280. PubMed ID: 27906048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.